Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07532148
PHASE1
Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sponsor: Chong Kun Dang Pharmaceutical
View on ClinicalTrials.gov
Summary
Clinical Trial to evaluate the pharmacokinetic Characteristics, safety and Tolerability among CKD-215 and D215
Official title: A Multicenter, Randomized, Open-Label, 2-Period Crossover Study to Evaluate Pharmacokinetics, Safety, and Tolerability of CKD-215 and D215 in Adults With Advanced BRCA-Mutated Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Key Details
Gender
FEMALE
Age Range
19 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2026-06
Completion Date
2027-08
Last Updated
2026-04-15
Healthy Volunteers
No
Conditions
Interventions
DRUG
CKD-215
2 tablets BID at 12-hour intervals for 7 days
DRUG
D215
2 tablets BID at 12-hour intervals for 7 days